Salley G Pels MD

Assistant Professor of Pediatrics (Hematology / Oncology); Associate Director, Yale Hemostasis Center

Clinical Interests

hematology; hemophilia; von Willebrand disease; bleeding disorders; clotting disorders; thrombophilia; thrombosis; platelet disorders; immune thrombocytopenia; alloimmune thrombocytopenia; oncology


Board Certifications

 
Pediatric Hematology-Oncology, Board Eligible
2009
Pediatrics, Board Certified

Patient Care Locations

 
salley_pelsfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Chordoma, Desmoid Tumor, Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, and Soft Tissue A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (COG 9902)
Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, and Lymphoid Leukemia Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (AALL0932) (CIRB)
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma, and Brain and Nervous System ANBL0032: PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (Ch14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
Childhood Infratentorial Ependymoma, Childhood Supratentorial Ependymoma, Newly Diagnosed Childhood Ependymoma, and Brain and Nervous System Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years (COG ACNS0831) (CIRB)
COMT Gene Polymorphism Pharmacogenetics of the Cannabinoid Response

More Clinical Trials...

Edit Profile